Hi-Risk/Recurrent/Advanced PCa Video Chat, Mar 12, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.
View AnCan’s patient-centered selection of papers and presentations from ASCO GU 2024, one of the top conferences on prostate cancer treatment: • ASCO GU 2024 conference highlights https://www.youtube.com/watch?v=YweU8hjA0Lw&t=2s
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: Joint pain and muscle pulls on Pluvicto — how long till they fade? (bn)
Topics Discussed
JimmyG losing sleep over his sleep — others weigh in; small PSA changes and oversized worries; Dr. Elisabeth Heath holds her own with a jokester — but seriously, it’s time to go back on treatment; abiraterone caveats; sore joints and muscle pulls on Pluvicto — how long till they fade?; urinary blood clots 2 years after radiation — doc gives him a bladder tour; darolutamide monotherapy holds the fort, and the hot flashes are finally going away; announcing a new AnCan group for caregivers of people with neuromotor conditions — like Parkinson’s, multiple sclerosis, muscular dystrophy — to be led by Alexa; insurance nixes denosumab for his rapid-onset osteoporosis and insists on Zometa — what’s up with that?; back stateside after overseas visit for radioligand therapy and a brief course of PARP inhibitor — signals are good so far; results of a study (LuPARP) that looked at that combination.
Hi-Risk/Recurrent/Advanced PCa Video Chat, Mar 4, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.
View AnCan’s patient-centered selection of papers and presentations from ASCO GU 2024, one of the top conferences on prostate cancer treatment: • ASCO GU 2024 conference highlights https://www.youtube.com/watch?v=YweU8hjA0Lw&t=2s
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: Here’s how to investigate if there’s a personalized/precision treatment for you (rd)
Topics Discussed
Exhaustive personalized/precision treatment pursuit; two successive Gents show us opposite sides of how a GU med onc beats a community practitioner; monotherapy enzalutamide; two more Gents manage their prostate cancer but not their heart issues; Dr. E is frank with an advanced patient but doesn’t reveal her cards just yet; our Gent thinks Guardant shows ‘weird’ results… or maybe they’re not so weird?; Pluvicto trumps olaparib in research and in practice; should spot RT metastatic directed therapy yield to systemic hormone treatment?; understanding the FDG scan
Chat Log
Jimmy Greenfield
sent: 6:22 PM
Mitoxantrone plus prednisone was previously accepted as standard chemotherapy for this stage of disease; however, docetaxel-based regimens have been shown to both palliate symptoms and prolong survival in hormone refractory prostate cancer.t.net
sent: 7:20 PM
Thank you, Rick, Dr. Bob, Len, and all, for a helpful discussion
Hi-Risk/Recurrent/Advanced PCa Video Chat, Feb 27, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.
In a special session before tonight’s meeting, we presented key papers from ASCO GU 2024, a major conference for doctors treating prostate cancer, and answered questions — details here.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: PSA rising but nothing on the PET scan – the tumor was hiding behind his bladder. (bn)
Topics Discussed
After beating back his cancer many times, he’s now neuroendocrine and wonders about options besides platinum (immuno, DLL3, alpha) — Dr. Rahul Aggarwal is likely to have answers; Tylenol on top of Orgovyx and darolutamide may have been one too drug too much for his liver; struggling to work remotely with Dr. E’s office team — you’ll need “a heavy dose of patience”; after 6 unhelpful chemo rounds, now seeing a good lutetium response, but unresponding tumors may be neuroendocrine; maximum out-of-pocket expense is the important number in choosing a Medicare Part D plan; trusting a broker for Medicare selection, and are Advantage plans a bad deal for cancer patients?; despite rising PSA, PSMA scan looked clear…turned out the tumor was hiding behind the bladder; good feedback on Dr. Elisabeth Heath; 90-day Lupron break to “catch my breath” — is restarting now a lost cause?; Lupron finally over, he’s switching back to a real bike from his e-bike…but when do the hot flashes stop?
Chat Log
Jim Marshall, Alexandria, VA · 5:34 PM
we all need to be our own best advocate at all times
Jim Marshall, Alexandria, VA · 6:05 PM
on a Macbook, I see all the names. without hovering
Len Sierra · 7:05 PM
Chromogranin A (CGA) and neuron-specific enolase (NSE) levels are biomarkers for NEPC. Also, synaptophysin and DLL3 (Delta-like Ligand 3) is positive in 76% of NEPC.
AnCan – rick · 7:06 PM
Contact: Garrett Crook 424-314-0745 Garrett.Crook@cshs.org Principal Investigator: Kanya Sankar, MD
AnCan – rick · 7:07 PM
DLL3 NCT04471727 https://classic.clinicaltrials.gov/ct2/show/NCT04471727?term=HPN328&cond=Prostate+Cancer&draw=2&rank=1
AnCan – rick · 7:14 PM
HPN328 is the DLL3 drug
AnCan – rick · 7:38 PM
Solo Arts Heal TOMORROW NIGHT rd + MARK KISSIN FRCS check https://ancan.org/solo-arts-heal/ for links to The Marsh page and join us on Zoom or YouTube
Thomas Matica · 7:54 PM
Did Rick say that there is video discussion on the insurance issues? I can’t find anything. Thanks.
AnCan – rick · 7:55 PM
Tom – search for Triage Cancer on our site
AnCan – rick · 7:56 PM
Here you go….. https://ancan.org/webinar-lets-talk-medicare-2024/
Patient Highlights from the 2024 ASCO GU conference
In a 75-minute “pre-game” before the 2/27/2024 meeting of the high-risk/recurrent/advanced prostate cancer group, moderators John, Rick, Ben, and Len discussed highlights from the just-concluded ASCO GU conference, a major meeting for genitourinary cancer specialists. They selected from hundreds of papers on prostate cancer presented in sessions and posters. We closed with a 30-minute audience Q&A.
What we covered:
Abi boosts olaparaib for BRCA
After triplet therapy, what next?
Less treatment, same cancer-fighting power
Trial of a neuroendocrine PCa drug
Prostate cancer and suicide
Germline & somatic testing is too infrequent
What treatments work after Pluvicto
Pluvicto flare largely lasts only one treatment
Community providers do poor job treating mCSPC men
Hi-Risk/Recurrent/Advanced PCa Video Chat, Feb 13, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: A penile prosthesis, and a lot of new hips. (bn)
Topics Discussed
Back on ADT, and now clobbered by fatigue — we suspect enzalutamide; exercise when walking’s too tough; he’s considering Pluvicto — but where’s the concordance scan?; FDG PET at low PSA?; when scanned, get the image CDs; new medonc OK’s ADT drug holiday at two years; more good reports on Dr. Bilusic; when dropping abi, taper prednisone cautiously; penile prosthesis surgery a success; insurance for yearly DEXA scans; urologists who don’t counsel on sexual dysfunction; making radiation a day at the beach; getting the word out on AnCan; hip issues and radiation; concerned about blood counts; shortness of breath and Flomax; drop abi, keep Lupron — or vice versa?; Peter K’s next move.
Chat Log
Alan Babcock · 7:21 PM
I have another meeting I have to attend. Hope to see everyone on Thursday.
Frank Fabish Columbus OH · 7:29 PM
has any read any information about the test trial of Anvirzel?
AnCan – rick · 7:35 PM
I know nothing about Anvirzel – but hopefully the Brains Trust can follow up
Frank Fabish Columbus OH · 7:37 PM
right. I think it is in Phase 1. not sure about PC trial. Hope to find out more info.
Len Sierra · 8:02 PM
For Frank Fabish: Anvirzel is a brand name for an aqueous extract of the plant Nerium oleander. Anvirzel contains two toxic cardiac glycosides, oleandrin and oleandrigenin. oleander is likely unsafe to take by mouth. It can cause a burning sensation in the mouth, nausea, vomiting, diarrhea, weakness, headache, stomach pain, serious heart problems, and many other side effects. Taking the oleander leaf, oleander leaf tea, or oleander seeds has led to deadly poisoning.
Frank Fabish Columbus OH · 8:03 PM
so I read about the extract
Frank Fabish Columbus OH · 8:14 PM
a friend of mine who had stage 4 metastatic PC with lesions on the brain. a brain bleed killed him Sunday. he was approved for this drug.
